FULGENT GENETICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
FULGENT GENETICS, INC. (FLGT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $8.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-30
- FULGENT GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $8.62M, a 14.10% decline year-over-year.
- FULGENT GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $9.89M, a 6.26% decline year-over-year.
- FULGENT GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $9.72M, a 11.02% decline year-over-year.
- FULGENT GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $10.04M, a 13.72% decline year-over-year.
- FULGENT GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $39.58M, a 11.01% decline from fiscal 2024.
- FULGENT GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $44.48M, a 3.63% increase from fiscal 2023.
- FULGENT GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $42.92M, a 31.50% increase from fiscal 2022.
- FULGENT GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $32.64M, a 105.52% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.62M 10-Q · filed 2026-07-30 | $18.51M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2026-03-31 | $9.89M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $39.58M 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $9.72M 10-Q · filed 2025-11-07 | $19.76M derived: sum of 2 quarters · filed 2026-07-30 | $30.31M derived: sum of 3 quarters · filed 2026-07-30 | |
| 2025-06-30 | $10.04M 10-Q · filed 2026-07-30 | $20.59M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $10.55M 10-Q · filed 2026-07-30 | |||
| 2024-12-31 | $44.48M 10-K · filed 2026-02-27 | |||
| 2024-09-30 | $10.92M 10-Q · filed 2025-11-07 | $22.55M derived: sum of 2 quarters · filed 2025-11-07 | $34.07M derived: sum of 3 quarters · filed 2025-11-07 | |
| 2024-06-30 | $11.63M 10-Q · filed 2025-11-07 | $23.15M derived: sum of 2 quarters · filed 2025-11-07 | ||
| 2024-03-31 | $11.52M 10-Q · filed 2025-11-07 | |||
| 2023-12-31 | $42.92M 10-K · filed 2026-02-27 | |||
| 2023-09-30 | $10.90M 10-Q · filed 2024-11-08 | $21.23M derived: sum of 2 quarters · filed 2024-11-08 | $31.49M derived: sum of 3 quarters · filed 2024-11-08 | |
| 2023-06-30 | $10.32M 10-Q · filed 2024-11-08 | $20.59M derived: sum of 2 quarters · filed 2024-11-08 | ||
| 2023-03-31 | $10.27M 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $32.64M 10-K · filed 2025-02-28 | |||
| 2022-09-30 | $8.97M 10-Q · filed 2023-11-03 | $17.00M derived: sum of 2 quarters · filed 2023-11-03 | $22.62M derived: sum of 3 quarters · filed 2023-11-03 | |
| 2022-06-30 | $8.03M 10-Q · filed 2023-11-03 | $13.65M derived: sum of 2 quarters · filed 2023-11-03 | ||
| 2022-03-31 | $5.62M 10-Q · filed 2023-11-03 | |||
| 2021-12-31 | $15.88M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | $4.37M 10-Q · filed 2022-11-07 | $7.90M derived: sum of 2 quarters · filed 2022-11-07 | $10.86M derived: sum of 3 quarters · filed 2022-11-07 | |
| 2021-06-30 | $3.53M 10-Q · filed 2022-11-07 | $6.49M derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2021-03-31 | $2.96M 10-Q · filed 2022-11-07 | |||
| 2020-12-31 | $8.16M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $3.15M 10-Q · filed 2021-11-09 | $4.23M derived: sum of 2 quarters · filed 2021-11-09 | $5.15M derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $1.08M 10-Q · filed 2021-11-09 | $2.00M derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $924.00K 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $3.21M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $951.00K 10-Q · filed 2020-11-09 | $1.69M derived: sum of 2 quarters · filed 2020-11-09 | $2.27M derived: sum of 3 quarters · filed 2020-11-09 | $2.87M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $737.00K 10-Q · filed 2020-11-09 | $1.32M 10-Q · filed 2019-08-12 | $1.92M derived: sum of 3 quarters · filed 2020-11-09 | $2.51M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-03-31 | $583.00K 10-Q · filed 2020-11-09 | $1.18M derived: sum of 2 quarters · filed 2020-11-09 | $1.77M derived: sum of 3 quarters · filed 2020-11-09 | $2.34M derived: sum of 4 quarters · filed 2020-11-09 |
| 2018-12-31 | $598.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $1.19M derived: sum of 2 quarters · filed 2020-03-13 | $1.76M derived: sum of 3 quarters · filed 2020-03-13 | $2.30M 10-K · filed 2020-03-13 |
| 2018-09-30 | $588.00K 10-Q · filed 2019-11-08 | $1.16M derived: sum of 2 quarters · filed 2019-11-08 | $1.71M 10-Q · filed 2018-11-09 | $2.29M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $573.00K 10-Q · filed 2019-11-08 | $1.12M 10-Q · filed 2019-08-12 | $1.70M derived: sum of 3 quarters · filed 2019-11-08 | $2.25M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-03-31 | $545.00K 10-Q · filed 2019-11-08 | $1.13M derived: sum of 2 quarters · filed 2019-11-08 | $1.68M derived: sum of 3 quarters · filed 2019-11-08 | $2.10M derived: sum of 4 quarters · filed 2019-11-08 |
| 2017-12-31 | $581.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $1.13M derived: sum of 2 quarters · filed 2019-03-22 | $1.55M derived: sum of 3 quarters · filed 2019-03-22 | $2.12M 10-K · filed 2019-03-22 |
| 2017-09-30 | $549.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $973.00K derived: sum of 2 quarters · filed 2017-11-13 | $1.54M 10-Q · filed 2017-11-13 | |
| 2017-06-30 | $424.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $989.00K 10-Q · filed 2017-08-14 | ||
| 2017-03-31 | $565.00K 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |